CEO Spiro Rombotis from Cyclacel Pharmaceuticals (NASDAQ:CYCC) says the team is planning to initiate a translational clinical study to evaluate their drug CYC065 in combination with venetoclax in chronic lymphocytic leukemia (CLL).
Rombotis says they expect to start enrolling patients in the first half and expects an output of data by the end of 2019. Rombotis says their $26 mln in cash will take them to the end of 2019, enough to hit the company's major milestones.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>